Strong revenue growth masks margin miss; execution risk elevated
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Revenue guidance on track (H1 ₹193 Cr vs. target ₹380-400 Cr annual). Margin guidance being missed by ~150 bps (23.9% actual vs. 25-30%).
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong revenue growth (102% YoY) and FY27 guidance tracking well (H1 ₹193 Cr toward ₹380-400 Cr target), but delivered Q2 margin of 23.9% fell short of 25-30% guidance due to raw material pricing and geopolitical pressure. FY28 growth target of ₹650-700 Cr is backed by concrete 1,200 MT expansion, but multiple new revenue streams (CDMO delayed to Q4, Medicos to Q3) remain unproven.
₹105.6 Cr
Revenue · +102.3% YoY₹17.2 Cr
Reported PAT · +84.4% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue growth 102.3% YoY, ₹105.61 Cr vs ₹52.2 Cr
METDelivered ₹105.6 Cr vs prior ₹52.2 Cr = 102.3% growth
PAT growth 84.4% YoY, ₹17.18 Cr vs ₹9.32 Cr
METDelivered ₹17.2 Cr vs prior ₹9.32 Cr = 84.4% growth
EBITDA margin recovery to 25%-30% range by Q3-Q4
OVERSTATEDQ2 actual margin 23.9% (EBITDA ₹25.24 Cr). Management acknowledges miss, blames raw material pricing pressure and geopolitical situation.
FY27 guidance ₹380-400 Cr on track
METH1 revenue ₹193.17 Cr (vs ₹85.5 Cr prior). At run-rate, tracking toward ₹380 Cr minimum.
Consolidated capacity 1,900-2,000 MT vs 400 MT prior
METManagement states 1,900-2,000 MT consolidated (Anlon stand-alone at 85-86% utilization, consolidated at 65-67%).
Earnings quality
What changed since the last call
Margin guidance maintained but at risk
DowngradePrior call (Q1): 'stabilizing margin 25%-30%'. Q2 actual: 23.9%. Management says 'temporary' due to geopolitics, aiming for 25%-27% by year-end, but near-term pressure evident.
CDMO timeline pushed back
DowngradeManagement said 'expecting first revenue Q3 FY27'; now confirmed delayed to Q4. Molecule 1 validation complete but commercialization depends on customer ramp-up (not counted in FY28 projections).
Capital raise delayed
Downgrade₹65-70 Cr equity raise for capex received approval in November. Funding needed for ₹130 Cr capex (₹70 Cr debt-funded). Timing risk could impact expansion pace.
FY28 guidance upgraded to ₹650-700 Cr
UpgradeNew forward guidance on Q2 call. Prior guidance was FY27 ₹350-400 Cr. FY28 adds 1,200 MT capacity by Q1, implies 67-80% growth.
The Q&A
Analysts pressed hard on margin miss (Vaibhav Mishra: 'can we expect margins above 24%?'), CDMO timeline (Rounak Baipai: 'when will first molecule commercialize?'), and acquisition impact (Bhavesh Patel: 'PAT margin decreasing, when steady-state?'). Management held up reasonably well, providing specific timelines (Q1 FY28 for expansion, Q4 for CDMO first revenue) and blaming external factors (raw material pricing) rather than operational issues. Some hedging on CDMO value-add ('too early to commit') and dividend ('will see cash flow first'). Overall, transparent but defensive tone.
FY27-FY28 revenue guidance — Nishita, Sapphire Capital
AnsweredFY27 ₹380-400 Cr, almost in line with prior target. On track. FY28 ₹650-700 Cr (excluding CDMO).
Margin sustainability — Vaibhav Mishra, Finvestors Research
PartialSituation improved from Q1. Achieved 23.9% in Q2. Hoping for 25%-26% by year-end as price revisions take effect. 23%-24% floor from raw material pressure; hope to reach 25%-27% sustainable.
Capacity expansion timeline — Vaibhav Mishra, Finvestors Research
AnsweredConstruction started. Finish first floor by end-November. Full commissioning by Q1 FY28. Possible 1-2 month delay if regulatory hurdles arise.
CDMO revenue timeline — Vaibhav Mishra, Finvestors Research
AnsweredDelayed 1-2 months past Q3. Expected end-Q3 or early-Q4. Depends on customer ramp-up; not yet included in FY28 revenue projections.
Margin profile by segment — Rounak Baipai, Wealthtime Advisory
AnsweredAPI ~35% gross EBITDA margin. Intermediate ~35%. Consolidated 65-67% utilization; Anlon stand-alone 85-86%.
CDMO commercialization and value-add — Rounak Baipai, Wealthtime Advisory
PartialMolecule 1 commercial supply delayed to Q3-Q4. Molecules 2-3 validation by Q1 FY28. Too early to commit value to FY28 guidance. 1-3 years to market acceptability. Right now, focused on existing business.
Acquisition integration and EBITDA margin — Bhavesh Patel, Patel Investments
PartialApiqo is lower margin (20%-23% EBITDA) vs. pharma. Acquisition just 6, 8 months old. By FY27 you'll see improvement in ROE. FY28 profitability will improve from CDMO and new products. Sustainability: 25%-27% EBITDA, 11%-14% PAT (or 11%-13% consolidated impact).
DMF filing progress — Prateek Srivastava, Nivesh Vista
Answered7 DMF planned in FY27. 3 almost done by Dec, another 2-3 by Q4. Ketoprofen US filing on hold pending customer (FDA trigger not yet started). ~6 DMF filed definitely by FY27, maybe 1-2 delayed.
Capital raise and debt — Deepak Chokhani, Raid Capital
Answered₹65-70 Cr planned for capex and acquisitions. Approval received in November. Allotment and call within next 8-10 days. Total capex ₹130 Cr (₹70 Cr debt-funded).
Dividend and cash flow outlook — Bhavesh Patel, Patel Investments
PartialEarly to commit on dividend. Management will see cash flow first. H1 FY27 operating cash flow ₹7.94 Cr vs ₹79.44 Cr prior year (WC improved). Aiming for cash flow positive by end-FY27.
Medical device (Anlon Medicos) ramp and revenue — Priyansh Miri, NGP Family Office
PartialRevenue starts Q3 FY27 (not material). FY28 ₹650-700 Cr base guidance excludes medical devices. Ointment topical gel expected Q1 FY28 DCGI approval; full pan-India launch. Revenue potential ₹70-80 Cr surgical devices business, ₹70-80 Cr ointment at peak.
Loxoprofen (Anlon Medicos) expansion — Priyansh Miri, NGP Family Office
AnsweredLoxoprofen topical gel: CDSCO and DCGI approval expected FY28 (earliest Q1 FY28). Pan-India marketing. Existing tablet/capsule ₹80-90 Cr; ointment 2x-3x higher. Not included in FY28 ₹650-700 Cr guidance yet.
China Plus One strategy and moat — Priyansh Miri, NGP Family Office
AnsweredNo China dependency in our Ketoprofen, Desketoprofen, Loxoprofen portfolio. We're replacing Chinese manufacturers globally. Cost at par or 10%+ cheaper than China. Registration is moat, not price.
Guidance
FY27 ₹380-400 Cr (reiterated)
HighH1 delivered ₹193.17 Cr; tracking well. Prior guidance from Q1 call maintained.
FY28 ₹650-700 Cr (new)
MediumBase business guided; excludes CDMO first revenue and medical device ramp (expected Q3 start). Backed by 1,200 MT expansion by Q1 FY28.
EBITDA 25%-30% (maintained from Q1 call)
LowQ2 actual 23.9%. Management targets 25%-27% recovery by year-end FY27; cites raw material normalization.
PAT margin 13%-14% core; 11%-13% consolidated
MediumApiqo acquisition at lower margin (20%-23% EBITDA). Consolidation drag evident; improvement expected as mix shifts toward higher-margin new products.
₹130 Cr capex FY27-FY28 (₹70 Cr debt, ₹65-70 Cr equity)
MediumEquity raise approval received November 2026. Debt funding to support Rajkot expansion (1,200 MT) and Apiqo capex.
Risks the call surfaced
Margin compression
HighQ2 margin 23.9% vs. 25%-30% guidance. Raw material (crude, petrochemical solvents) pricing post-geopolitical spike. Apiqo at 20%-23% margin (lower than Anlon core).
New product timing risk
HighCDMO first molecule delayed to Q4 (from Q3 guidance). Anlon Medicos surgical implants to start Q3 but minimal FY27 revenue. Loxoprofen ointment DCGI approval awaited (Q1 FY28 expected).
Integration execution risk
MediumApiqo (43.7% of H1 revenue) and Biozotic (11.7%) acquired early FY27; lower margin profile (20%-23% EBITDA vs. core 25%-27%). Consolidation drag evident in PAT margin.
Regulatory approval risk
Medium7 DMF filings planned in FY27 (3 done by Q2, 6 by year-end targeted). Ketoprofen US filing on hold pending customer FDA trigger. Loxoprofen ointment DCGI approval expected Q1 FY28 but on hold for complexity and stability data.
Capacity expansion execution
MediumConstruction underway; finish first floor by end-November. Full commissioning targeted Q1 FY28 but at risk from regulatory/statutory approvals (mentioned 1-2 month possible delay).
Working capital cycle
LowReceivables annualized 123 days (improved but still elevated). Payables 40 days. Management targeting 170-180 day optimal working capital cycle. Current position strains cash availability.
Management
Score 7/10. Clear and detailed on financial metrics and timelines. Transparent on margin miss (blames external factors, not opex). Candid on regulatory delays and project timelines. Some hedging on CDMO value-add and dividend. Revenue track record strong (102% YoY growth, H1 ₹193 Cr on guidance track). Margin guidance missed (23.9% vs. 25%-30%); management acknowledges and explains but recovery credibility tested. Acquisitions integrated (6-8 months old) but still drag on profitability.
1 · Q3 FY27 (Nov-Dec 2026)
Anlon Medicos revenue first contribution from surgical implants; DMF filings 3-4 more planned
2 · Q4 FY27 (Jan-Mar 2027)
CDMO first molecule commercial supply to start; Loxoprofen topical DCGI approval expected
3 · Q1 FY28 (Apr-Jun 2027)
Rajkot capacity expansion (1,200 MT, 8 new clean lines) commissioned; Anlon Biologies first revenue
FY28 growth target of ₹650-700 Cr is backed by concrete 1,200 MT expansion, but multiple new revenue streams (CDMO delayed to Q4, Medicos to Q3) remain unproven.
Informational and educational content only. Not investment advice.